Suven Life Sciences commences phase 1 clinical trial of NCE SUVN-D4010 in USA

02 Sep 2015 Evaluate

Suven Life Sciences has commenced phase 1 clinical trial of NCE SUVN-D4010 in USA. SUVN-D4010 is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer’s disease and other dementias.

The company submitted Investigational New Drug Application (IND) to US FDA to conduct Phase-1 clinical trial for Cognition in Alzheimer’s disease, under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA) which was assigned an IND number 126099.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

168.05 5.00 (3.07%)
30-Dec-2025 09:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1716.25
Dr. Reddys Lab 1271.35
Cipla 1488.05
Zydus Lifesciences 899.90
Lupin 2082.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×